The Joint Blog

NOVEMBER 4, 2019

The study found that 58% of physicians agree that “medical cannabis was a legitimate medical therapy.” ” However, as noted by NORML, around half of respondents “expressed discomfort in talking to their patients about medical cannabis options, a finding that is also consistent with prior data. A majority (>?50%)

Therapy 42

Therapy Clinical Trials Conditions Patients 42

Cannabis Law Report

DECEMBER 8, 2021

Global Psychiatry Partnering 2014 to 2021 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Access to headline, upfront, milestone and royalty data. Specific therapy indication. Advanced Cooling Therapy. Upfront payment value.

Access 52

Access Data Pharmaceutical Research and Development 52

Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. IGC) engages in the development of cannabinoid-based therapies for healthcare applications. million individuals in the U.S.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. IGC), based in Maryland, engages in developing cannabinoid-based therapies for healthcare applications.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

AUGUST 3, 2021

Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Medxtractor Corp.

Research and Development 105

Research and Development Data Conditions Therapy 105

Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. Of course, legalization and education efforts can only go so far without data, and that’s where RoC’s research initiatives come into play.

Advocacy 96

Advocacy Patients Clinical Trials Education 96

Veriheal

OCTOBER 20, 2021

Always consult a physician before attempting psychedelic therapy. Data from a nationally representative sample of participants have been collected since 1975 to understand drug use trends among American young adults, and noteworthy findings are published each fall. Cannabis and magic mushrooms for the win! A Magical Future.

Therapy 98

Therapy Microdosing Decriminalization Consumption 98

Veriheal

JUNE 30, 2023

Researchers say this emphasizes just how important it is that psilocybin therapy be done in a controlled setting with therapy and community-based after-care. The 14-page document covers several aspects of the drug development process, including trial best practices, data collection, and new drug application requirements.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Cannabis Law Report

JUNE 23, 2021

Medicann is launching an observational study using RYAH Smart Dry Herb Inhalers in order to collect patient feedback on consumption of cannabis strains available on the Island, including strains supplied by Aurora Europe , a subsidiary of Canadian-headquartered Aurora Cannabis Inc., About RYAH Group, Inc. RYAH Group, Inc.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.” ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

SpeedWeed

SEPTEMBER 17, 2021

million to assess the efficacy of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI). Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Lately, MAPS research zeroed in on MDMA-assisted therapy for PTSD.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

AUGUST 2, 2021

The diversified venture fund is focused on tackling the growing global mental health crisis by investing in innovative psychedelic-based and adjacent therapies that are poised to shape the future of psychiatry and fields beyond. Innovative psychedelic-based and adjacent therapies are poised to shape the future of psychiatry and fields beyond.

Research and Development 98

Research and Development Therapy Collective Treatment 98

Cannabis Law Report

DECEMBER 11, 2021

The clinic established the UK Medical Cannabis Registry to offer patients medical cannabis products at a reduced price while collecting and analysing clinical data from real-world evidence “to expand our understanding of medical cannabis in the UK”. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

Cannabis Law Report

SEPTEMBER 2, 2021

The Contract contains no minimum testing requirement; it stipulates a fixed monthly fee for sample collection site services and a separate fixed fee per individual COVID-19 test. The initial Contract term is one year and includes two one-year options for renewal exercisable at the College’s discretion.

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

AUGUST 3, 2021

Testing under the Contract will commence in early August 2021, and all sample collection sites will be fully operational before the start of the academic year on August 25. Applied DNA is also the manufacturer of the EUA-authorized Linea™ COVID-19 Assay Kit.

Clinical Trials 105

Clinical Trials Therapy Collective Research and Development 105

Cannabis Law Report

JUNE 2, 2021

Samples will be collected via anterior nasal swabs that offer ease-of-use for all ages. Pooled surveillance testing of all campers will be conducted prior to the start of each of two summer sessions and once on-site.

Clinical Trials 82

Clinical Trials Therapy Research and Development Collective 82

Cannabis Law Report

NOVEMBER 11, 2021

The City should create a data collection reporting system for any interactions involving psilocybin for ongoing public safety monitoring. The City should determine how psilocybin therapy can be applied to address mental health issues in Denver. 2021-Comprehensive-Report. Source: [link].

Policy 52

Policy Decriminalization Safety Therapy 52

The Joint Blog

APRIL 25, 2019

“We also sought to collect data on other pertinent outcomes related to the use of cannabis to enhance understanding of the potential benefits this complementary therapy offers.” No significant weight change was noted over 335 day average duration of therapy.

Therapy 48

Therapy Collective Patients Treatment 48

Cannabis Law Report

JUNE 30, 2021

Despite the tremendous promise of psychedelics, there are no large-scale standardized clinical trials or data sources that clinicians can use to guide their patient decisions. Building the Data Backend. Psychedelics and psychotropics and their potential application to mental health afflictions are SHAMAN’s initial target. Disclaimer.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Veriheal

OCTOBER 29, 2020

Of that, the American National Institute on Drug Abuse (NIDA) has invested just over $1 billion and has allocated far more money to researching cannabis misuse and the negative effects of consuming cannabis and its compounds as a form of therapy. The data for this graphic was provided by Jim Hudson at Hellth.com. . Canada, and the U.K)

Pharmaceutical 98

Pharmaceutical Therapy Cannabinoids Chronic Pain 98

Cannabis Law Report

NOVEMBER 3, 2021

This collectively brings the Company’s total clinic count to 15 globally. Zerenia™ Clinics UK follows the high-quality standards of personalised cannabinoid-based therapies and pursues precision-based medicine with the central goal to improve patient access to cannabinoid-based therapies.

Therapy 52

Therapy Access Patients Treatment 52

Cannabis Law Report

NOVEMBER 23, 2021

Additionally, it validates the Company’s supply chain business model of providing psilocybin for clinical use and research, adding to previously announced supply partnerships this year with Mycrodose Therapeutics , Mycotopia Therapies , Cube Psytech , Allied Health , ATMA Journey Centers , Revive Therapeutics and HealthTech Connex.

Supply Chain 52

Supply Chain Research and Development Pharmaceutical Compliance 52

Cannabis Law Report

JANUARY 18, 2022

ADCL’s safeCircle program is a fully integrated testing platform for enterprise and educational institutions that provides a full range of COVID-19 diagnostic testing and associated services, including sample collection, test site infrastructure design and management, results tracking, and vaccination status management. Dr. James A.

Research and Development 52

Research and Development Therapy Supply Chain Collective 52

CannaMD

SEPTEMBER 10, 2020

Is it safe to continue cannabis-based therapies during pregnancy? This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented.

Marijuana 59

Marijuana Therapy Data THC 59

Cannabis Law Report

JANUARY 31, 2022

These doses are produced under Good Agricultural and Collection Practices and tested for potency and impurities to support patient safety and practitioner confidence. At this time, Numinus Bioscience said that it is prepared to supply psilocybin in whole mushroom form, through three packaged doses equivalent to 10, 15, and 25mg of psilocybin.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

DECEMBER 9, 2021

These describe technology and infrastructure for the collection of precise, multimodal, multivalent data that can be processed via machine learning, artificial intelligence, signal processes, and other statistical methods to yield clinically meaningful output to satisfy the requirements of the IFU. NEW YORK , Dec.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

The Cannigma

NOVEMBER 11, 2021

Researchers analyzed the data self-reported by the 18 participants and found statistically significant differences (which adds power and confidence to the results) between the experimental conditions in many of the items and scales used. CBD alters the subjective effects of THC.

CBD 139

CBD Research and Development THC Environment 139

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

OCTOBER 12, 2021

Mary Hartnett, Director of Medical Services at Sarah Lawrence College, stated, “safeCircle was our choice given the convenience of its on-site sample collection process, access to high-sensitivity RT-PCR-based testing with rapid turnaround times, ability to scale with our needs, and capacity to ease our administrative burdens.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Canna Law Blog

APRIL 13, 2019

These products have not been shown to be safe or effective, and deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”. Specifically, the agency fears that.

CBD 90

CBD Safety Topical Food 90

Cannabis Law Report

JULY 27, 2021

If successful, researchers will analyze the data to quantify global gene expression and will use available pipelines to determine differential gene expression between the three lines sampled. The UC Davis scientists will also test new approaches to extract RNA from dried material.

Research and Development 98

Research and Development Pharmaceutical Sativa Extraction 98

The Joint Blog

FEBRUARY 24, 2021

Volume 33 of Complementary Therapies in Medicine states that 40% of patients with Parkinson’s Disease or Multiple Sclerosis are already self-medicating with cannabis. It discusses a study approved by The Colorado Multiple Institutional Review Board used to collect anonymous data from a wide range of patients.

Treatment 55

Treatment Clinical Trials Collective Patients 55

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Findings based on NPDS data do not necessarily reflect the opinions of AAPCC. exposures to any substance(s).

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

MARCH 31, 2022

While much of the marketing behind Measure 109 focused on “psilocybin therapy,” there is no requirement for clients to receive a medical diagnosis before accessing services. Currently available data is not fully reliable as there are shortfalls in research methodology and data collection.

Microdosing 52

Microdosing Legalization Dispensary Data 52

Cannabis Law Report

JUNE 17, 2021

Silo Wellness is a publicly traded company on the CSE with a consumer-facing platform for the sale of functional mushroom products, psilocybin mushroom production in Jamaica, and the facilitation of psychedelic wellness retreats in both Jamaica and Oregon that incorporate a variety of psychedelic-augmented therapies. ir@silowellness.com.

Research and Development 75

Research and Development Therapy Access Media 75

The Joint Blog

AUGUST 30, 2020

Many seniors likely experimented first-hand with cannabis during their youth and are now returning to it as a potential therapy to mitigate many of the health-related symptoms that come with older age, including chronic pain. “These results are hardly surprising,” NORML said in a press release.

Marijuana 52

Marijuana Chronic Pain Events Therapy 52